Skip Navigation



Neuro-Oncology Advance Access published online on October 20, 2009
Neuro-Oncology, doi:10.1093/neuonc/nop010
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mautner, V.-F.
Right arrow Articles by Panse, J.
PubMed
Right arrow Articles by Mautner, V.-F.
Right arrow Articles by Panse, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author(s) 2009. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2{dagger}

Victor-Felix Mautner, Rosa Nguyen, Hannes Kutta, Carsten Fuensterer, Carsten Bokemeyer, Christian Hagel, Reinhard E. Friedrich and Jens Panse

Department of Maxillofacial Surgery (V.M., R.N., R.E.F.); Department of Otolaryngology (H.K.); Institute of Neuropathology (C.H.); Department of Oncology/Hematology, Cancer Center (J.P., C.B.); University Medical Center Hamburg-Eppendorf, Hamburg, Germany; MRI Institute, Hamburg Othmarschen, Germany (C.F.)

Corresponding Author: Victor-Felix Mautner, MD, Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany (kluwe{at}uke.uni-hamburg.de).


  Abstract

Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.

Keywords: bevacizumab, neurofibromatosis type 2, vestibular schwannoma

Received May 12, 2009; Accepted May 29, 2009

{dagger} As we were submitting this manuscript, Dr Scott Plotkin informed us that their manuscript describing the outcome of bevacizumab treatment on NF2 patients was accepted for publication in the New England Journal of Medicine.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.